VA
EIGR

VR Adviser’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

VR Adviser’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-48,992
Closed -$12.2M – 33
2022
Q1 		$12.2M Buy
+48,992
New +$7.74M 1.98% 15

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VR Adviser's EIGR Position: Q2 2022 in Review

VR Adviser sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2022, closing a stake of 48,992 shares — an estimated $12.2M sold.

VR Adviser first reported a position in EIGR in Q1 2022 and held it in 1 quarter. The position peaked at $12.2M in Q1 2022. 91 funds tracked by Wall St. Rank hold EIGR as of Q2 2022.

  • VR Adviser reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
  • VR Adviser sold 48,992 Eiger BioPharmaceuticals, Inc. shares in Q2 2022, an estimated $12.2M.
  • VR Adviser first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2022 and held it in 1 quarter.
  • VR Adviser's Eiger BioPharmaceuticals, Inc. position peaked at $12.2M in Q1 2022.
  • 91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2022.

Based on VR Adviser's 13F filing for Q2 2022, filed 15 Aug 2022.